Everyone assumes tissue engineering means biologics pathways. But has anyone actually tested whether the same therapeutic outcome can be achieved through medical device classification instead?

The Timeline Reality: FDA device pathway (510k): 108-124 days. Biologics pathway (BLA): 6-10 months post-filing, plus 2-3 years of clinical trials. For identical patient outcomes, device classification is 3x faster to market.

The Classification Loophole: According to PMC8335953, tissue-engineered products get classified based on "primary mechanism of action." If your scaffold works through physical/mechanical action → medical device. If it works through biological action → biologic. Same outcome, different regulatory universe.

Strategic Reframing: Most tissue engineering tries to prove biological activity — growth factor release, cellular signaling, immune modulation. But what if we optimize for mechanical function instead? Acellular scaffolds achieving tissue repair through structural support qualify for 510(k) clearance by demonstrating "substantial equivalence" to existing devices.

Translation Precedent: Skin substitute companies already exploit this. Animal-derived acellular products: device pathway, 4-6 months. Human cell-seeded products: biologics pathway, 3-5 years. Patients get repaired skin either way — but device classification gets them treated 5x faster.

The Engineering Challenge: Can we design tissue scaffolds that achieve therapeutic outcomes through mechanical properties alone? Advanced computational models show that scaffold architecture, porosity, and degradation kinetics determine healing outcomes more than growth factor content. Engineers optimize the wrong variables because they're aiming for the wrong regulatory pathway.

Patient Reality Check: A patient with a non-healing wound doesn't care whether their treatment works through "mechanical guidance of tissue regeneration" (device) or "growth factor-mediated cellular activation" (biologic). They care about speed to treatment and clinical outcome.

BioDAO Translation: Most tissue engineering BioDAOs default to biologics pathways because that's what the literature emphasizes. But device-focused engineering could get their innovations to patients years faster. Same therapeutic outcome, completely different regulatory strategy.

The Question That Matters: How many tissue engineering therapies currently in biologics development could achieve equivalent patient outcomes through device-optimized mechanical design? My hypothesis: 40-60% of programs are targeting the wrong pathway.

The translation bottleneck isn't the technology — it's regulatory classification strategy. Time to think like an engineer, not a biologist.